Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann H Partridge

Showing results (321-330 of 363) with videos related to

Pageof 37
Sort By:
Breast Cancer Research and Treatment|November 13, 2012
Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus ConferenceMasakazu Toi, John R Benson, Eric P Winer, et al.
NPJ Precision Oncology|February 26, 2026
Tumor genomics in patients younger than 40 years of age with metastatic breast cancerKristen D Brantley, Ananya Kodali, Gregory J Kirkner, et al.
The New England Journal of Medicine|March 5, 2015
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapyHalle C F Moore, Joseph M Unger, Kelly-Anne Phillips, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2023
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast CancerMatteo Lambertini, Marcello Ceppi, Richard A Anderson, et al.
NPJ Breast Cancer|May 24, 2022
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trialsSaranya Chumsri, Zhuo Li, Daniel J Serie, et al.
Journal of the National Cancer Institute|January 9, 2026
Postpartum breast cancer: evidence for a distinct phenotypeMark E Sherman, Lola Etievant, Robert A Vierkant, et al.
JAMA Oncology|December 12, 2024
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical TrialAnn H Partridge, Terry Hyslop, Shoshana M Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2024
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast CancerErica L Mayer, Yue Ren, Nikhil Wagle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2020
Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence RiskBarbara Pistilli, Angelo Paci, Arlindo R Ferreira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2019
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast CancerSara M Tolaney, Hao Guo, Sonia Pernas, et al.
Pageof 37

Showing results (321-330 of 363) with videos related to

Sort By:
Pageof 37
Breast Cancer Research and Treatment|November 13, 2012
Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus ConferenceMasakazu Toi, John R Benson, Eric P Winer, et al.
NPJ Precision Oncology|February 26, 2026
Tumor genomics in patients younger than 40 years of age with metastatic breast cancerKristen D Brantley, Ananya Kodali, Gregory J Kirkner, et al.
The New England Journal of Medicine|March 5, 2015
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapyHalle C F Moore, Joseph M Unger, Kelly-Anne Phillips, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2023
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast CancerMatteo Lambertini, Marcello Ceppi, Richard A Anderson, et al.
NPJ Breast Cancer|May 24, 2022
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trialsSaranya Chumsri, Zhuo Li, Daniel J Serie, et al.
Journal of the National Cancer Institute|January 9, 2026
Postpartum breast cancer: evidence for a distinct phenotypeMark E Sherman, Lola Etievant, Robert A Vierkant, et al.
JAMA Oncology|December 12, 2024
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical TrialAnn H Partridge, Terry Hyslop, Shoshana M Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2024
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast CancerErica L Mayer, Yue Ren, Nikhil Wagle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2020
Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence RiskBarbara Pistilli, Angelo Paci, Arlindo R Ferreira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2019
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast CancerSara M Tolaney, Hao Guo, Sonia Pernas, et al.
Pageof 37